Locations:

Blood Cancers

October 7, 2021/Cancer/Blood Cancers

Less-Intensive Therapies for Acute Myeloid Leukemia Tied to Higher Mortality Risks

Study reports on 11-year experience in AML

April 1, 2021/Cancer/Blood Cancers

CAR T-Cell Therapy Shows Promise in Treating Relapsed/Refractory Multiple Myeloma

Preliminary trial reports positive patient response

March 8, 2021/Basic & Translational Science

Molecular and Genetic Mechanisms in Bone Marrow Failure Syndromes and Myeloid Neoplasia

Results of two studies presented at the 2020 ASH Annual Meeting

February 24, 2021/Cancer/Blood Cancers

Azacitidine Shows Potential as a Treatment for Multiple Myeloma

Trial results point the way to further investigation

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

January 20, 2021/Basic & Translational Science

Selective Targeting May Have Therapeutic Potential in TET2-Mutant Neoplasia

TETi76 eliminates TET2-mutant and TET-deficient cancer cells

January 7, 2021/Cancer/Blood Cancers

Pacritinib Moves Closer to FDA Approval for Myelofibrosis

Dose-finding trial adds to evidence of efficacy

December 29, 2020/Basic & Translational Science

Machine Learning Improves the Subclassification and Prognostication of Acute Myeloid Leukemia

Four genomic clusters identified

December 14, 2020/Cancer/Blood Cancers

Decision Support Tool Can Predict Patient Response to Treatment with Hypomethylating Agents

A major advance in prognosis for myelodysplastic syndromes that may improve outcomes

December 10, 2020/Basic & Translational Science

Metabolomic Screening Reveals Pre-Existing Signatures in Patients Treated with CAR T-Cell Therapy

Molecular markers could potentially predict major adverse side effects

November 16, 2020/Cancer/Blood Cancers

How to Talk to Your Cancer Patients About Their COVID-19 Risk

Dr. Mikkael Sekeres in his latest New York Times column

BackPage 3 of 8Next